Rokit Healthcare, a regenerative medicine company, is experiencing a significant surge in its stock price following the announcement of the world's first clinical trials for kidney regeneration.
As of 9:37 a.m. on July 14, the company’s shares rose by 5,050 won (13.76%) to 41,750 won. At one point, the stock increased by as much as 22.75%, reaching 45,200 won.
The surge in investor sentiment is attributed to the news that Rokit Healthcare, in collaboration with Asan Medical Center, has commenced the world's first clinical surgeries for kidney regeneration.
Rokit Healthcare announced that it received approval for advanced regenerative medicine clinical trials from the Institutional Review Board (IRB) at Asan Medical Center, allowing it to begin human clinical surgeries this month.
Following the completion of the trials, Rokit Healthcare plans to pursue expedited approval procedures for advanced regenerative therapies. Earlier, the institutions received approval from the Ministry of Health and Welfare for their advanced regenerative medicine research plan in May and have completed all necessary regulatory processes.
A representative from Rokit Healthcare stated, "If this clinical trial is successful, it could change the existing treatment paradigm centered on dialysis and kidney transplants. We will accelerate research and development to provide new treatment options for chronic kidney disease patients both domestically and internationally."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.